Author: jezzabellemente

WASHINGTON, March 11 (Bernama-GLOBE NEWSWIRE) — Egg Medical, a leader in enhanced radiation protection devices (ERPD), today announced the results of a Late-Breaking Trial presented at the Cardiovascular Research Technologies (CRT) 2026 conference. The study, presented by Santiago Garcia, MD, of The Christ Hospital, confirms that the addition of the EggNest™ system reduces levels of scatter radiation to all members of the interventional team to the extent that users could do procedures safely without the use of lead aprons or wear ultralight aprons.

“For decades, the interventional community has accepted a trade-off: protect your long-term health from the effects of radiation exposure by wearing heavy lead aprons at the cost of damaging your back and joints,” said Santiago Garcia, MD, the study’s lead presenter. “This data proves that we no longer must choose. By using the EggNest system, we can provide the entire team with protection that is superior to the status quo, by either going apron-free, or while wearing aprons that feel like a light vest. This is about ensuring that the next generation can have healthy careers without the physical toll.” 

The Key Study Findings:

• Annualized collar dose (in mrem) over lead aprons is 25.5 for the primary operator, 9.8 for assistant, and 10.2 for the nurse. When combined with ultralight aprons, total annualized body doses dropped to 1.41 for primary operator, 2.1 for assistant and 1.0 for the nurse.
• At these levels, a clinician would have to work for an entire career to receive the same radiation dose they currently receive in just one year under the standard of care.
• The study confirmed that whether clinicians choose to go apron-free, or wear aprons that are 55% lighter than standard lead, the entire team remained below traditional exposure levels using traditional methods.

Modern labs are not one-size-fits-all. Under the banner of “Protection Is Personal,” the company is championing a responsible approach that allows clinicians to choose whether they want to go apron free.

“Our goal is to give clinicians a choice—but one backed by rigorous, published data,” said Gavin Philipps, Chief Commercial Officer. “Choice isn’t a weakness; it’s how responsible safety programs operate. By providing personalized data through live dosimetry, the EggNest supports apron-free or ultralight apron workflows where approved, rather than forcing a specific behavior.”

A photo accompanying this announcement is available at 
https://www.globenewswire.com/NewsRoom/AttachmentNg/548c258c-72cd-4a18-a8cb-e5066a8688cc

Contact:
Susan Storm
sstorm@eggmedical.com

SOURCE: Egg Medical, Inc.

–BERNAMA

Positioning Subang Jaya Medical Centre Among the World’s Leading Hospitals and Strengthening Malaysia’s Standing as a Trusted Healthcare Destination
 
SUBANG JAYA, March 10 (Bernama) — Subang Jaya Medical Centre (SJMC) has been named among the Top 250 hospitals globally and top 10 regionally in Newsweek’s World’s Best Hospitals 2026, placing it among a select group of leading hospitals worldwide. The recognition highlights SJMC’s commitment to international standards of clinical care and patient outcomes, further strengthening its position as one of Malaysia’s Top 3 private hospitals for three consecutive years.
 
Bryan Lin, Chief Executive Officer of SJMC and Regional Chief Executive Officer of Asia OneHealthcare, said the achievement reflects the collective effort of its clinical and operational teams. “Being named among Newsweek’s World’s Best Hospitals Top 250 is a proud moment for all of us at SJMC. It reflects the trust our patients place in us and the dedication of our doctors, nurses, and healthcare professionals who work tirelessly to deliver world-class expertise every day.”
 
“This recognition is not about a single milestone. It represents years of building strong clinical foundations, investing in advanced technology, and nurturing a culture where patients remain at the heart of every decision,” he added.
 
The annual ranking by Newsweek, conducted in collaboration with global data research firm Statista, evaluates more than 2,500 hospitals across 32 countries. The assessment is based on recommendations from medical experts worldwide, patient experience data, hospital quality metrics, and Statista’s Patient Reported Outcome Measures (PROMs) assessment.
 
SJMC’s inclusion in the 2026 Top 250 builds on a series of international accolades in recent years, reflecting consistent performance across specialties and service quality. The hospital has been listed among Newsweek’s Asia’s Top Private Hospitals and ranked Top 1 in Asia for Hip Surgery and Replacement for two consecutive years. It also retained its position as Malaysia’s most listed hospital in Newsweek’s Asia Pacific 2025 rankings.
 
These global recognitions follow SJMC’s endorsement as one of only four Flagship Medical Tourism Hospitals 2025 by the Ministry of Health Malaysia, highlighting the hospital’s growing role in representing Malaysia in regional and international healthcare. In line with the Malaysia Year of Medical Tourism 2026, SJMC continues to contribute to the country’s reputation as a preferred destination for high quality medical treatment and recovery. The hospital receives patients from across Asia Pacific and beyond, supported by its multidisciplinary expertise and comprehensive care.
 
Complementing these achievements, SJMC continues to uphold rigorous quality and safety standards. It is the first hospital in Asia Pacific to hold four Australian Council on Healthcare Standards International (ACHSI) Centre of Excellence certifications in Oncology, Cardiology, Gastroenterology and Paediatric services, in addition to its three Joint Commission International (JCI) and six Malaysian Society for Quality in Health (MSQH) accreditations.
 
Bryan Lin added, “As a Malaysian hospital recognised on a global platform, we see this as both an honour and a responsibility. We will continue to strengthen our specialised services, including building a highly experienced, multidisciplinary neurology and neurosurgery team to advance complex brain care and ensure patients receive treatment aligned with global benchmarks.”
 
With more than four decades of experience, SJMC remains committed to expanding medical excellence and advancing innovation to further elevate person-centred care, while supporting Malaysia’s healthcare goals.
 
For more information, visit https://subangjayamedicalcentre.com/.
 
ABOUT SUBANG JAYA MEDICAL CENTRE (SJMC)
SJMC is part of Asia OneHealthcare (A1Health), a leading healthcare provider in the region. With an impeccable reputation as one of Malaysia’s most trusted private medical centres, SJMC is best known for its clinical outcomes. The hospital is an award-winning 442-bed multi-disciplinary tertiary hospital providing comprehensive and complex care in all specialities.
 
It is one of the few internationally accredited Joint Commission International (JCI) hospitals in Malaysia and Malaysian Society for Quality in Health (MSQH) accredited. SJMC’s laboratory is also an internationally recognised MS ISO 15189 accredited since 2009. In 2024, SJMC Oncology (Cancer), Cardiology, Gastroenterology and Paediatric Services are certified by Australian Council of Healthcare Standards International (ACHSI) as a Centre of Excellence, making it the first in Asia-Pacific.
 
SJMC is recognised as a finalist for the Flagship Medical Tourism Hospital Programme 2023 – 2025 by Malaysia Healthcare Travel Council (MHTC) to establish Malaysia as a globally renowned icon for healthcare travel, delivering exceptional end-to-end patient experiences anchored on medical excellence, service excellence, and international branding. It receives both local patients across Malaysia and international patients across the Asia Pacific with over 47,000 admissions and almost half a million outpatient visits annually.
 
SOURCE: SUBANG JAYA MEDICAL CENTRE (SJMC)
 
FOR MORE INFORMATION, PLEASE CONTACT: 
Impact Communications (M) Sdn Bhd
Name: Harmini Nair
Tel: +6016-253 6206
Email: harmini@impactcommunications.com.my

Name: Teereth Kaur
Tel: +6019-956 8440
Email: teereth@impactcommunications.com.my
 
–BERNAMA

KUALA LUMPUR, March 10 (Bernama) — InterSystems, a creative data technology provider powering over one billion health records globally, announced the appointment of Tim Ferris as vice president (VP), Healthcare Practice.

In a statement, InterSystems said the announcement was timed to coincide with healthcare leaders gathering for the 2026 HIMSS Global Health Conference & Exhibition.

InterSystems President, Don Woodlock said Dr Ferris’s experience as a physician, healthcare executive and policy leader makes him well positioned to help develop technology solutions that support stakeholders across the healthcare ecosystem.

In his new role, Dr Ferris will help guide the clinical and strategic direction of the company’s healthcare solutions worldwide. He will also advise global health systems and governments while supporting the development of technology solutions, including those involving artificial intelligence (AI) in care delivery.

Most recently, Dr Ferris served as president of healthcare at Red Cell Partners, a technology incubator and investment firm. Prior to that, he was national director of transformation at England’s National Health Service (NHS), where he oversaw digital transformation initiatives, including expanding the NHS app to more than 40 million users and migrating national data services to the cloud.

Before the NHS, Dr Ferris was chief executive officer and chair of the Massachusetts General Physicians Organization and senior vice president for population health at Mass General Brigham.

In those roles, he oversaw 3,000 physicians and led an accountable care organisation that generated over US$1 billion in cumulative cost savings for taxpayers while achieving top national performance on quality metrics. (US$1=RM3.94)

Dr Ferris is a Harvard-trained physician and professor of medicine at Harvard University. He has authored more than 120 publications on quality measurement, health information technology, and population health and currently serves in an advisory role for Stanford University.

— BERNAMA